FDA · United States
bevacizumab — FDA regulatory status
bevacizumab (ABEVMY) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- ABEVMY
- Originator
- Amgen
- Mechanism
- Vascular endothelial growth factor A inhibitor
- Target
- Vascular endothelial growth factor A, long form
- Structured fields
- 8
Sponsor / originator context: Amgen. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Vascular endothelial growth factor A inhibitor. Target: Vascular endothelial growth factor A, long form. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 132 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 20210081 | Phase 3 | Amgen | 2022-502352-31-00 |
| 61186372COR3002 | Phase 3 | Janssen-Cilag International N.V | 2024-513853-66-00 |
| ABC-HCC | Phase 3 | George Institute for | 2024-512953-26-00 |
| BEATcc | Phase 3 | Ningbo Cancer Hospital | 2024-514179-17-00 |
| BEVACIZUMAB, ERLOTINIB | Phase 3 | Telethon Foundation | 2024-516843-15-00 |
| BOOG 2010-02 Stop&Go study | Phase 3 | Teva Pharma | NCT01935492 |
| BRADI ICO-2023-15 | Phase 3 | CERo Therapeutics | 2024-510893-25-00 |
| BX44273 | Phase 3 | HOFFMANN-LA ROCHE | 2023-504263-16-00 |
| Bevacizumab | Phase 3 | Pfizer | NCT00631371 |
| Bevacizumab | Phase 3 | HOFFMANN-LA ROCHE | NCT00528567 |
| Bevacizumab | Phase 3 | HOFFMANN-LA ROCHE | NCT00486759 |
| Bevacizumab | Phase 3 | Samsung Bioepis | NCT02754882 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026039538 | MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS | WO |
| 2025230528 | MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE | WO |
| 2025250277 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | US |
| 2025147499 | LUTIKIZUMAB DESTINÉ À ÊTRE UTILISÉ DANS UN TRAITEMENT DE L'HIDRADÉNITE SUPPURÉE | WO |
| 4563165 | PSMA-STEAP1-IMMUNGLOBULIN (DVD-IG)-MOLEKÜLE MIT ZWEIFACH VARIABLER DOMÄNE UND ARZNEIMITTELKONJUGATE | EP |
| 2025059280 | METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE | US |
| 2025057837 | Methods for Treating HCV | US |
| 2025049789 | METHODS OF TREATING ALOPECIA ARAETA | US |
| 2025034157 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | US |
| 11542526 | Oncolytic adenoviral vector and methods of use | US |
| 10167452 | Viral purification methods | US |
| 9523691 | Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis | US |
Related hubs
FAQ
What is the FDA approval status of bevacizumab?
bevacizumab currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get bevacizumab regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to bevacizumab?
This spoke lists 132 published programs associated with bevacizumab in our pipeline index.